ICI therapies take effect by overcoming the inhibition of classic immune checkpoints, such as PD-1, PD-L1 and CTLA-4 on anti-tumor immune lymphocytes, particularly CD8+ cytotoxic T cells and NK cells, thereby reactivating bodies’ anti-tumor immune response. Here, CD8A is linked to neoplasm.